General Information of Drug (ID: DMOFIBM)

Drug Name
LMT-X Drug Info
Synonyms Second-generation tau aggregation inhibitor (Alzheimer's disease); Second-generation tau aggregation inhibitor (Alzheimer's disease), TauRx
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 3 [1]
Alzheimer disease 8A20 Phase 3 [2]
Cross-matching ID
TTD Drug ID
DMOFIBM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PP-007 DMZS5RN Ischemic stroke 8B11.5Z Phase 1 [6]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Davunetide DMD7K9X Cognitive impairment 6D71 Phase 3 [7]
TRx0237 DM0QNF4 Alzheimer disease 8A20 Phase 3 [8]
E2814 DMZ3Q59 Alzheimer disease 8A20 Phase 2/3 [9]
PBT-2 DMKWGS1 Alzheimer disease 8A20 Phase 2 [10]
RG6100 DMEFD0B Alzheimer disease 8A20 Phase 2 [4]
Tau-binding PET tracer DM9QFW2 Alzheimer disease 8A20 Phase 2 [7]
BIIB092 DM263RP Progressive supranuclear palsy 8A00.10 Phase 2 [4]
Semorinemab DMA17VD Alzheimer disease 8A20 Phase 2 [11]
Bepranemab DMRQIJO Alzheimer disease 8A20 Phase 2 [12]
JNJ-63733657 DMMKWGJ Alzheimer disease 8A20 Phase 2 [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Microtubule-associated protein tau (MAPT) TTS87KH TAU_HUMAN Inhibitor [3]
TAR DNA binding protein 43 (TARDBP) TT9RZ03 TADBP_HUMAN Inhibitor [4]
Tau protein aggregation (TauA) TTZGF8B NOUNIPROTAC Modulator [5]

References

1 ClinicalTrials.gov (NCT01689246) Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034429)
3 Clinical pipeline report, company report or official report of TauRx.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease. Correction in: volume 31 on page 81.
6 ClinicalTrials.gov (NCT04677777) A Randomized, Phase 1, Contemporaneously Controlled, Multicenter Study to Assess the Safety of PP-007 in Subjects With Acute Ischemic Stroke. U.S.National Institutes of Health.
7 Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
8 Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296.
9 Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathol Commun. 2020 Feb 4;8(1):13.
10 PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
11 Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13(593):eabb2639.
12 Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18.
13 ClinicalTrials.gov (NCT04619420) A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease. U.S.National Institutes of Health.